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A turkey erythrocyte phospholipase C (PLC) has been in-
strumental in delineating the role of G-proteins in receptor-
regulated inositol lipid signalling. This isoenzyme is uniquely
regulated both by α-subunits of the Gq family and by G-protein
βγ-subunits. A 4819 bp cDNA encoding this PLC has been
cloned from a turkey erythrocyte cDNA library. The open
reading frame of this cDNA encodes a 1211-amino-acid protein
(calculated molecular mass 139050 Da) that contains amino acid
sequences of 16 peptides sequenced from the turkey erythrocyte
PLC. The predicted sequence of the turkey PLC shows con-
siderable similarity with the sequences of previously cloned
members of the PLC-β family, with the highest identity (71%)
shared with PLC-β2 and lesser identities observed with PLC-β1
(49%), PLC-β3 (46%) and PLC-β4 (37%). The largest differ-
ences in sequence between the turkey PLC-β and other PLC-β
isoenzymes occur in the C-terminal domain and in the region
INTRODUCTION
The inositol-lipid specific PLC isoenzymes have been divided
into PLC-β, -γ, and -δ1 families on the basis of both structural
and functional similarities [1,2]. Isoenzymes of the PLC-β family
are activated by G-protein-coupled receptors through both
pertussis toxin-insensitive and -sensitive pathways. The major
mechanism whereby PLC-β isoenzymes are regulated apparently
involves activation by α-subunits of the Gq family of pertussis
toxin-insensitive G-proteins [3–6]. The physiological relevance
of the pertussis toxin-sensitive pathway and the identity of the
G-proteins involved are not fully established. However, since G-
protein βγ-subunits directly activate certain PLC-β isoenzymes





probably accounts for the pertussis
toxin-sensitive regulation of PLC.
The turkey erythrocyte is a useful model for the study of
G-protein-regulated PLC. The high levels of P
#Y
-purinergic re-
ceptor- and guanine nucleotide-promoted PLC activity retained
by membranes prepared from these cells has permitted detailed
kinetic analyses [12–14]. Moreover, the availability of large
quantities of erythrocytes has facilitated purification of protein
components of an inositol lipid signalling pathway from a
homogeneous cell type. A 150 kDa PLC (PLC-βt) was purified
from a cytosolic fraction prepared from these cells [15] and was
demonstrated by membrane reconstitution to be a receptor- and
Abbreviations used: pfu, plaque-formimg units ; PLC, phospholipase C; (r)PLC-βt, (recombinant) turkey erythrocyte PLC-β ; RT-PCR, reverse
transcriptase-dependent PCR; TFA, trifluoroacetic acid.
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between the X- and Y-domains. The turkey isoenzyme and PLC-
β2, which differ in their regulation by G-protein α-subunits, are
only 44% similar across the approx. 400 amino acid residues of
the C-terminal domain that has been implicated in αq activation
of these proteins. Recombinant turkey PLC-β was purified to
homogeneity following expression from a recombinant baculo-
virus in Sf9 insect cells. The immunoreactivity and mobility on
SDS}PAGE of the recombinant enzyme were the same as
observed with native turkey erythrocyte PLC-β. Moreover, the
catalytic activities of the recombinant enzyme were indistinguish-
able from those of native turkey erythrocyte PLC-β in assays
carried out in the presence of cholate and Ca#+, or in assays of
activity after reconstitution with Gα
""
or G-protein βγ-subunits.
The turkey PLC-β was more sensitive to activation by Gα
""
than
was PLC-β2, and was more sensitive to activation by βγ-subunits
than either PLC-β2 or PLC-β1.
G-protein-regulated enzyme [16]. Peptide sequencing indicated
that PLC-βt was a unique enzyme with sequence identity to
PLC-β isoenzymes [17]. PLC-βt was used to establish a phospho-
lipid vesicle reconstitution assay for a PLC-activating G-protein
that subsequently was purified to homogeneity from turkey
erythrocytes [5]. Peptide sequencing of this G-protein and
molecular cloning of the avian cDNA unambiguously established
this signalling protein to be Gα
""
[18]. Other work has led to
molecular cloning and expression of the turkey erythrocyte
P
#Y
-purinergic receptor that activates Gα
""
[19].
Here we report the cloning of cDNA encoding the PLC-β
cohort of this three-component inositol lipid signalling cascade.
Recombinant PLC-βt (rPLC-βt) has been expressed using the
baculovirus expression system and purified to homogeneity, and
the equivalence of the activities of PLC-βt and rPLC-βt has been
established. Potential differences in the regulatory properties of
rPLC-βt, rPLC-β1 and rPLC-β2 have been explored.
MATERIALS AND METHODS
Purification of native proteins
Receptor- and G-protein-regulated PLC-βt was purified from
turkey erythrocyte cytosol as previously described in detail
[15,20]. Avian Gα
""
was purified from cholate extracts of turkey
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erythrocyte membranes [5,21], and G-protein βγ-subunits were







The amino acid sequence of purified native PLC-βt was obtained
from HPLC-purified peptides derived from two separate prepara-
tions. Eight peptide sequences of a tryptic digest of purified PLC-
βt were previously reported [17]. Two of these sequences were
obtained from a single HPLC reverse-phase column fraction
that apparently consisted of a mixture of two peptides. These
were reported as (vi) EVVISSEPQTASLA and (vii)
SY(T}H)QLPFTXL [17]. Subsequent comparison of these two
peptide sequences with the deduced amino acid sequence of the
turkey erythrocyte cDNA clone 24B-1A reported in this paper
suggests that the underlined amino acids were incorrect in the
original report. Modification of the previously reported peptide
sequences to EV(T}H)QLPEPQTASLA (Table 1, peptide 7) and
SYVISSFTXL (Table 1, peptide 6) would be consistent with the
deduced amino acid sequence of clone 24B-1A. Eight additional
peptide sequences were obtained from a separate preparation of
purified PLC-βt as described below (Table 1, peptides 9–16).
Approx. 200 µg of purified PLC-βt was concentrated to 0.2 ml
by rotary evaporation. The protein was denatured and disulphide
bonds reduced by incubating for 4 h at ambient temperature in
the presence of 6 M guanidine hydrochloride, 10 mM dithio-
threitol, 2 mM EDTA and 250 mM Tris, pH 8.5. The protein
was carboxymethylated by addition of 0.1 vol. of 200 mM
iodoacetic acid, the tube was purged with N
#
gas, and the sample
was incubated for 30 min in the dark at ambient temperature.
The sample was applied to a Vydac C-4 reverse-phase HPLC
column equilibrated in 0.1% trifluoroacetic acid (TFA) and
eluted with a linear gradient of 0.1% aq. TFA to 0.1% TFA in
acetonitrile}propan-2-ol (3 :1, v}v) over 60 min at a flow rate of
1.0 ml}min. The peak fraction of PLC-βt was dried by rotary
evaporation, dissolved in 70 µl of 70% formic acid and treated
overnight at room temperature with 20 mg of CNBr. The CNBr
cleavage products were dried by rotary evaporation, dissolved in
100 µl of 6 M guanidine hydrochloride, 100 mM Tris, pH 8.5,
100 mM dithiothreitol, and applied to a Vydac C-4 reverse-phase
HPLC column equilibrated with 0.1% TFA. The peptides were
eluted with a linear gradient from 0 to 80% solvent B [aceto-
nitrile}propan-2-ol (3 :1, v}v), 0.085% TFA] over 90 min at a
flow rate of 1 ml}min. Two well resolved peptides, 15 and 16
(retention times 70.4 and 75.1 min respectively), were concen-
trated and the amino acid sequences determined. Material eluting
as a broad peak of absorbance from the C-4 column
(54.0–57.0 min) was pooled, dried, dissolved in 100 µl of 1%
ammonium bicarbonate and digested for 24 h at 37 °C with
0.01 µg of trypsin. Six tryptic peptides resolved on a Vydac C-18
reverse-phase HPLC column were concentrated by rotary evap-
oration and sequenced on an Applied Biosystems 475A Protein
Sequencer.
Oligonucleotide primers
The following five degenerate inosine-containing oligonucleotide
primers were prepared on a Cyclone Plus DNA synthesizer
(MilliGen}Bioresearch) : P14, ATG(C}A)GICCIGA(A}G)ATI-
GA(T}C)GA(A}G)ATITTTAC (peptide 14; amino acid residues
4–13; sense) ; P16, GGITG(C}T)TCITG(T}C)GTIGA(G}A)-
(C}T)TIGA (peptide 16; amino acid residues 8–16; sense) ;
P15r, AA(T}A)GG(G}A)TCAAA(T}C)TG(T}C)TT(G}A)TC
(peptide 15; amino acid residues 3–9; antisense) ; P4r,
IGCIACIGC(A}G)TCIGGIAC(G}A)TA(G}A)TC (peptide 4;
amino acid residues 1–8; antisense) ; Px, TG(A}G)TT(T}C)-
TCAAAIGAIA(G}A)IAT (common PLC-β X-domain peptide
ILSFENH; antisense). Primers for sequencing or PCR ampli-
fication of sequences used as probes were synthesized as perfect
match primers (21–24 bases in length).
Preparation of turkey erythrocyte mRNA
Washed packed erythrocytes (approx. 24 ml) were prepared as
described previously [14] from 100 ml of adult female turkey
whole blood and homogenized with a Brinkman polytron homo-
genizer in 128 ml of 4.0 M guanidine isothiocyanate, 16.7 mM
sodium citrate, pH 7.0, 144 mM β-mercaptoethanol and 0.17%
(v}v) anti-foam A (Sigma). Then 8 ml of 10% (w}v) sodium
laurylsarcosinate was added to give a final concentration of
0.5%. The homogenate was centrifuged at 4000 g for 10 min and
the supernatant was recovered and layered on 15.5 ml of 5.7 M
CsCl, 10 mM EDTA, 16.7 mM sodium acetate, pH 5.0. The
samples were centrifuged at 113000 g for 24 h, and the resultant
RNA pellets were dissolved in diethyl pyrocarbonate-treated
water. The RNA was further purified by sequential extraction
with phenol (water saturated)}chloroform (1:1, v}v) and then
with chloroform, and was precipitated with ethanol. The final
yield of total RNA was 2.2 mg. Poly(A)+ mRNA was purified on
two sequential oligo(dT)–cellulose spin-columns (5 Prime-3
Prime) according to the manufacturer’s directions, yielding
approx. 150 µg of poly(A)+ mRNA. Total RNA from other
turkey tissues was prepared by the method of Chomczynski and
Sacchi [23] for use in RNase protection assays.
Reverse transcriptase-dependent PCR (RT-PCR)
Reverse transcription of mature turkey erythrocyte poly(A)+
mRNA was carried out with 1 µg of mRNA primed with either
50 pmol of oligo(dT)
"'
or 300 pmol of a degenerate gene-specific
primer using the GeneAmp RNA-PCR kit (Perkin-Elmer Cetus)
according to the manufacturer’s specifications. The temperature
cycles were 42 °C for 60 min, 99 °C for 5 min and 5 °C for 5 min.
Following reverse transcription, 300 pmol of gene-specific for-
ward and reverse [oligo(dT)-primed reaction only] primers was
added and the cDNA amplified by PCR at a final MgCl
#
concentration of 2 mM. The reaction cycles for PCR ampli-
fication were 4.5 min at 95 °C, then 35 cycles at 95 °C for 45 s,
37 °C for 30 s and 72 °C for 1.5 min. The extension step of the
final cycle was increased to 10 min at 72 °C. RT-PCR products
were analysed on agarose gels, and bands of the predicted size
were excised from low-melt agarose, ligated into the SmaI
restriction site of pUC-18K and transformed into competent
MC1061 cells for further analysis and double-stranded se-
quencing.
Construction and screening of the turkey erythrocyte cDNA library
Methylated first-strand cDNA was synthesized from 5 µg of
adult turkey erythrocyte poly(A)+ RNA using the λ-ZAP cDNA
synthesis kit (Stratagene) according to the manufacturer’s pro-
tocol. A XhoI restriction site was introduced into the 3« end of the
cDNA via a XhoI}oligo(dT)
")
adaptor}primer during reverse
transcription of the poly(A)+ RNA. The yield of cDNA following
second-strand synthesis was approx. 2 µg, and the cDNA ranged
in size from 0.6 to 8.0 kb. EcoRI adaptors were blunt-end ligated
to the double-stranded cDNA, adaptor ends were phosphoryl-
ated and the cDNA was digested with XhoI prior to size
fractionation through a Sepharose CL-4B column. Approx.
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100 ng of the " 1 kb cDNA pool was ligated with EcoRI}XhoI-
digested λ-ZAPII and the library packaged with Gigapack II
Gold (Stratagene). The primary library contained 3.6¬10(
plaque-forming units (pfu) that were " 99% recombinant bac-
teriophage. A portion of the primary library (1.2¬10' pfu) was
amplified to a final titre of 8.9¬10"" pfu}ml.
The cDNA library was screened with a probe derived from a
pUC18K (pUC18 with the kanamycin phosphotransferase gene
in place of the β-lactamase gene) plasmid containing the RT-
PCR DNA P16}P4r. This plasmid was used as the template for
a second PCR reaction using primers located in the 3« portion of
the X-region and the 5« portion of the Y-region (corresponding
to 24B-1A nucleotides 1619–1642 and 2045–2068 respectively ;
see Figure 1). The resulting 450 bp PCR product was labelled
with [α-$#P]dCTP to a specific radioactivity of 1.1¬10* c.p.m.}µg
by random priming and used to screen the turkey erythrocyte
primary cDNA library (1.2¬10' recombinant plaques) at high
stringency. Hybridization was carried out for 16 h at 42 °C with
150 ng of $#P-labelled probe in 50% formamide, 6¬SSPE, 0.5%
SDS and 100 µg}ml salmon sperm DNA. Following hybrid-
ization, the filters were washed three times at 50 °C for 10 min
each in 0.1¬SSC containing 0.1% SDS. Plaques hybridizing
with the probe were identified by autoradiography and purified.
pBluescript containing the cDNA clone was rescued from the
purified λ phage by in io excision utilizing the ExAssist}SOLR
system (Stratagene) according to the manufacturer’s recom-
mendations. The size of each clone was analysed by restriction
digestion analysis. One of these clones, 24B-1A (4.8 kb), was
chosen for further analysis.
cDNA sequencing
Clone 24B-1A was sequenced manually on both strands from
double-stranded plasmid using the Sequenase Version 2.0 DNA
sequencing kit (United States Biochemical). Four vector-specific
and 33 gene-specific primers (18 sense and 15 antisense) chosen
to yield overlapping sequences were prepared on a Cyclone Plus
DNA synthesizer (MilliGen}Biosearch). The accuracy of double-
stranded sequencing was confirmed by subcloning the 5 kb insert
from an XbaI}XhoI digest of 24B-1A.pBS into the XbaI}SalI
restriction sites of bacteriophage M13 (both mp18 and mp19)
and sequencing the resulting single-stranded DNA with both
dGTP and dITP nucleotide mixes. Thus each strand of clone
24B-1A was independently sequenced three times. Overlapping
sequences within each strand were assembled into a contiguous
file using the MacVector AssemblyLign software, and the sense
and antisense strands were compared to yield the final consensus
sequence (see Figure 1). Sequence comparisons of the turkey
clone 24B-1A with seven other members of the PLC-β family
were made with MacVector 4.5 sequencing software and the CD-
ROM formatted Entrez:Sequences database (release 17.0 ; June
15, 1995;NationalCenter forBiotechnology Information,NCBI)
on a Power Macintosh 8100.
Ribonuclease protection assays
A 587 bp BglII}EcoRI fragment of cDNA clone 24B-1A (nucleo-
tides 2786–3372) was subcloned into BamHI}EcoRI-digested
pBluescript II (SK−). The new construct was linearized with PstI
(there are two internal PstI restriction sites in the insert), and
run-off antisense cRNA transcripts (approx. 370 nt) were gener-
ated for use as a radiolabelled probe using T7 RNA polymerase
in the presence of [α-$#P]CTP. Ribonuclease protection assays
were performed with 5 µg of turkey erythrocyte total RNA,
0.7 µg of erythrocyte mRNA or 5 µg of total RNA from other
turkey tissues using an Ambion RPA II kit according to the
manufacturer’s protocol. The reaction products were resolved on
a 4% acrylamide (19:1 acrylamide}bisacrylamide)}8 M urea
gel. Autoradiographs of the gel were developed following an
overnight exposure.
Expression and purification of recombinant proteins
The 5« untranslated sequence of the turkey erythrocyte PLC
cDNA clone 24B-1A was reduced from 361 to 62 bp by
PCR amplification of nucleotides 300–916 of 24B-1A. The
upstream primer GAGAGAGAGCGGCCGCAGGAGGAG-
TAAACTGTGTGA incorporated a NotI restriction site on the
5« end of the cDNA and hybridized to nucleotides 300–319 of
clone 24B-1A (Figure 1). The reverse primer TAATGCTG-
CTTCCACCCTCTT, equivalent to nucleotides 896–916 of clone
24B-1A, was located downstream of a unique internal BamHI
restriction site (nucleotides 481–486). The 633 bp PCR product
was purified over a QIA quick-spin PCR purification column
(Qiagen), digested with NotI and BamHI, and cloned into NotI-
and BamHI-digested 24B-1A.pBS. This resulted in the replace-
ment of the 361-base 5«-untranslated sequence with 62 bp of
5«-untranslated sequence. The fidelity of the new construct was
confirmed by sequencing the plasmid on both strands. Turkey
erythrocyte PLC cDNA was subsequently subcloned from pBS
into the NotI and XhoI restriction sites of the mammalian
expression vector pcDNA3 (Invitrogen) and from pcDNA3 into
the NotI and XbaI restriction sites of the baculovirus transfer
vector pAcMP2 (Pharmingen). Positive clones were confirmed
by restriction digests.
Monolayer cultures of Spodoptera frugiperda (Sf9) cells were
co-transfected with BaculoGold (Pharmingen) and the 24B-
1A.pAcMP2 vector. Recombinant baculovirus was purified
through two rounds of plaque purification. Plaques expressing
rPLC-βt were identified by immunoreactivity with anti-PLC-βt
polyclonal antisera (g246) and by quantification of PLC activity.
A 3.2 litre suspension culture of Sf9 cells (3.9¬10* cells)
adapted to serum-free medium was infected at a multiplicity
of infection of 3 with the recombinant baculovirus encoding
PLC-βt. Infected cells were maintained in serum-free medium
(IPL-41; 1% lipid concentrate, 4 g}l yeastolate ultrafiltrate,
100 units}ml penicillin, 100 µg}ml streptomycin, 0.25 µg}ml
amphotericin B) at 27 °C for 48 h. Cells were harvested by
centrifugation for 5 min at 500 g. The cell pellet was resuspended
in 700 ml of ice-cold lysis buffer containing 10 mM Tris, pH 7.4,
5 mM MgCl
#
, 2 mM EGTA, 0.2 mM benzamidine, 0.2 mM
PMSF, 1 µg}ml pepstatin, 1 µg}ml leupeptin and 1 µg}ml
aprotinin. The resuspended cells were homogenized using 10
strokes in a Dounce homogenizer and centrifuged at 100000 g
for 45 min. The supernatant was collected as the cytosolic fraction
and rPLC-βt was purified by sequential chromatography through
columns of Q-Sepharose FF, hydroxyapatite, heparin–Sepharose
4B, Sephacryl S-300 and Mono-Q FPLC as previously described
for PLC-βt [15,20]. rPLC-β1 and rPLC-β2 were purified from
Sf9 cells as described previously [24].
PLC assays
Total PLC activity was measured as previously described [15,20].
Briefly, 5 µl of sample was assayed for 5 min at 30 °C in a final
volume of 100 µl. The final assay mixture contained 10 mM
Hepes, pH 7.4, 120 mM KCl, 10 mM NaCl, 2 mM EGTA,
5.8 mM MgSO
%
, 0.5% (w}v) sodium cholate, 2.1 mM CaCl
#
to
give approx. 100 µM free Ca#+, 50 µM PtdIns(4,5)P
#
and approx.
20000 c.p.m. of Ptd[$H]Ins(4,5)P
#
. Reactions were terminated by
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addition of 375 µl of chloroform}methanol}HCl (40:80:1, by
vol.), 125 µl of chloroform and 125 µl of 0.1 M HCl.
[$H]Ins(1,4,5)P
$
released into the aqueous upper phase was
quantified in a liquid scintillation counter.
Gα
""
and βγ-subunits were reconstituted with PLC in




serine using the dialysis protocol described by Boyer et al. [9,25].
The time of incubation and amounts of Gα
""
, βγ-subunit and
PLC are indicated in the Figure legends.
SDS/PAGE and immunoblot analysis
SDS}PAGE was performed on gels consisting of 8.5% acryl-
amide and 0.23% bisacrylamide. Gels were stained with silver
nitrate, or proteins were transblotted on to nitrocellulose and
analysed as previously described [17] for immunoreactivity with
either rabbit polyclonal antisera 246 raised against purified
PLC-βt or with PLC-β1- or PLC-β2-specific peptide antisera
[24].
RESULTS
Two independent preparations of purified PLC-βt were subjected
to proteolytic cleavage by trypsin, CNBr or CNBr followed by
trypsin, and the proteolytic fragments were resolved on an
HPLC reverse-phase column. The amino acid sequences of the
16 proteolytic peptides isolated by this procedure are shown in
Table 1. Peptide 10, isolated from the double digest of PLC-βt
with CNBr and trypsin, corresponds to a portion of peptide 8
that was isolated after cleavage with trypsin alone.
Degenerate oligonucleotide primers were designed based on
the amino acid sequence of PLC-βt peptides 4, 14, 15 and 16
(Table 1) and on the amino acid sequence ILSFENH (corre-
sponding to residues 404–410 of human PLC-β2), which is
Table 1 PLC-βt peptide sequences
The amino acid sequences of HPLC-purified peptides isolated from digests of purified native
PLC-βt were determined as described in the Materials and methods section. Peptides 1–8 were
isolated from a tryptic digest of PLC-βt and the amino acid sequences were reported previously
[17]. Peptides 9–16 were obtained using a second preparation of purified PLC-βt from which
peptides 15 and 16 were isolated after CNBr digestion and peptides 9–14 were isolated after
double digestion with CNBr followed by trypsin. Underlined amino acids correspond to
sequences from which degenerate oligonucleotide primers were designed for RT-PCR. Small
capital letters indicate amino acid residues which differ from the deduced sequence of clone
24B-1A. The corresponding amino acid residues in clone 24B-1A are shown

















highly conserved among members of the PLC-β family. PCR
amplification was carried out using reverse-transcribed adult
turkey erythrocyte mRNA as a template and the primer pairs
P16}P15r, P16}P4r and P14}Px. DNA fragments of 0.95, 1.35
and 0.57 kb were produced from the three sets of primers. The
PCR fragments were subcloned into pUC18K, sequenced, and
overlapping sequences were identified. Translation of the 1770 bp
composite sequence resulted in an amino acid sequence that
exhibited high similarity with amino acid residues 221–802 of
bovine PLC-β1 and amino acids 217–804 of human PLC-β2. The
predicted amino acid sequence of the PCR-amplified turkey
DNA contained the sequences (96% identity) of 10 of the
peptides resolved from purified PLC-βt.
A 450 bp DNA fragment (equivalent to nucleotides 1619–2068
of clone 24B-1A; see Figure 1, dotted underline) was amplified
from plasmid containing the 1.35 kb P16}P4r PCR product and
used as a probe for high-stringency screening of an adult turkey
erythrocyte λ-ZAP cDNA library. A total of 24 positive clones
of various lengths were isolated. Restriction digests and partial
sequencing of 15 of the cDNA clones indicated that they
corresponded to the same gene. The nucleic acid and deduced
amino acid sequences of a full-length clone for PLC-βt (24B-1A)
are illustrated in Figure 1. The salient features include: 4819
bases total length, 361 bases of 5« untranslated sequence, 3633
bases of an open reading frame encoding 1211 amino acids
(calculated molecular mass 139050 Da), and 825 bases of 3«
untranslated sequence. Predicted amino acid sequences cor-
responding to the 16 peptide sequences obtained from PLC-βt
are distributed throughout the deduced sequence, and 149 of the
156 total amino acid residues are identical within the deduced
amino acid sequence.
Comparisons of the amino acid sequence deduced from turkey
clone 24B-1A were made with seven other members of the PLC-
β family. The highest identity (71%) was found with human
PLC-β2 (Figure 2, top panel). The order of similarity between
PLC-βt and other members of the PLC-β family is : bovine PLC-
β1, 49% ; human PLC-β3, 46% ; Xenopus PLC-Xβ, 44% ; rat
PLC-β4, 37% ; Drosophila PLC-21, 37% ; Drosophila Norp A
PLC, 32%. The highest identity with the other PLC-β isoenzymes
occurs in the X-and Y-domains (64–92%), while the lowest
exists in the intervening region between the X- and Y-domains
and in the C-terminal region (7–44%). The alignment of PLC-β2
with PLC-βt (Figure 2, lower panel) reveals three regions of
striking dissimilarity between them. The first (22% identity)
occurs in the 49-amino-acid region flanked by the X- and Y-
domains (residues 468–516 of PLC-βt). A 186-amino-acid
stretch between residues 822 and 1007 of PLC-βt has 36%
identity with PLC-β2, whereas a 66-amino-acid portion of the
C-terminal region (1146–1211), which has been implicated as
an area important for G-protein regulation of PLC, shows
only 15% identity. The last 22 amino acids of the C-terminus of
PLC-βt are not present in PLC-β2.
Consensus sites for cAMP-dependent protein kinase
phosphorylation are underlined in Figure 2 (lower panel). Six of
the sites present in PLC-βt are not found in PLC-β2 (Ser-475,
-784, -847, -862, -923 and -1066), and PLC-β2 contains three sites
not found in PLC-βt (Ser-256, -884 and -960) ; the two enzymes
share three sites (Ser-252, -599 and -610). Two of the PLC-βt
sites (Ser-475 and -923) are notable since corresponding sites are
not present in PLC-β2 and hydropathy analysis predicts a high
probability of surface exposure of these sites in the tertiary
structure of the enzyme. Elevation of cAMP levels in turkey
erythrocytes markedly reduces G-protein-activated PLC activity
in membranes isolated from these cells (M. C. Galas and T. K.
Harden, unpublished work).
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Figure 1 cDNA and deduced amino acid sequences of PLC-β t
The nucleotide and predicted amino acid sequences of clone 24B-1A are presented. Amino acid sequences corresponding to peptide sequences obtained from purified native PLC-β t are double-
underlined. Nucleotide sequence corresponding to the 450 bp probe used for screening the cDNA library (nucleotides 1619–2068) is identified by a dotted underline. cDNA sequence corresponding
to the run-off antisense cRNA transcript employed as a probe in RNase protection assays (nucleotides 3058–3372) is identified by a dotted underline. Regions of the nucleotide sequence
corresponding to the two PCR primers and the internal Bam H1 restriction site used for subcloning 24B-1A into mammalian and baculovirus expression vectors are identified with a single underline
(nucleotides 300–318, 896–916 and 481–486 respectively).
The tissue distribution of PLC-βt mRNA was assessed in
various turkey tissues using an RNase protection assay (Figure
3). The highest levels of 24B-1A mRNA expression occurred in
adult erythrocytes. Much lower levels of mRNA (10% of
expression levels in erythrocytes) were observed (in descending
order) in lung, kidney, heart, brain and liver. PLC-βt mRNA was
not detected in skeletal muscle or intestine.
The baculovirus expression system was used to express rPLC-
βt with the goal of confirming that the physical and regulatory
properties of the protein encoded by the cloned 24B-1A cDNA
correspond to those of the native PLC-βt enzyme. Expression of
rPLC-βt, determined by immunoreactivity and enzyme activity
(results not shown), was observed within 12–24 h of infection of
Sf9 cells and reached maximal levels within approx. 48 h. Approx.
55% of the recombinant protein was recovered in the cytosolic
fraction isolated after lysis of infected Sf9 cells.
A cytosolic fraction was prepared from Sf9 cells after 48 h of
infection with the recombinant PLC-βt baculovirus, and recom-
binant enzyme was purified to homogeneity using chromato-
graphic steps previously established for purification of native
PLC-βt [15,20]. rPLC-βt exhibited chromatographic properties
that were identical to those of the native enzyme. Although
rPLC-βt could be purified to homogeneity with fewer chromato-
graphic steps, comparison of the elution properties of the native
and recombinant enzymes under these well established conditions
provided additional evidence for their similarity. The availability
of purified rPLC-β1 and rPLC-β2 also allowed a comparison of
the recombinant and native turkey enzymes with other PLC-β
isoenzymes. rPLC-βt and PLC-βt co-migrated on SDS}PAGE
with a similar mobility to rPLC-β1 and a lower mobility than
rPLC-β2 (Figure 4A). The recombinant and native turkey
enzymes were immunologically indistinguishable and were dis-
tinct from PLC-β1 and PLC-β2 (Figures 4B–4D).
The total enzymic activities of purified PLC-βt and rPLC-βt
were compared (Figure 5). Equal molar amounts of each enzyme
produced similar rates of hydrolysis of either PtdIns(4,5)P
#
or
PtdIns4P. Enzyme activities were linear with respect to enzyme
concentration (Figure 5, upper panel) and incubation time
(results not shown). Each enzyme exhibited a rate of hydrolysis
of approx. 15–20 µmol}min per mg when assayed with 200 µM
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Figure 2 Alignment of PLC-βt with other PLC-β isoenzymes
PLC-β isoenzymes were aligned as described in the Materials and methods section. Upper panel : linear schematic representation comparing PLC-β t with seven other PLC-β isoenzymes. Open
boxes represent the highly conserved X- and Y-domains. Amino acid number is indicated above each diagram, and the percentage sequence identity with the corresponding regions of PLC-β t is
indicated below each diagram. The overall percentage identity with PLC-β t is indicated in parentheses on the left. Drosoph¯ Drosophila. Lower panel : comparison of the PLC-β t amino acid sequence
deduced from the turkey erythrocyte cDNA clone 24B-1A with human PLC-β2. Dots (.) indicate amino acid identity with PLC-β t. The hyphens represent gaps introduced to improve alignment.
Consensus phosphorylation sites for cAMP-dependent protein kinase are double-underlined. The asterisk (*) indicates the stop codon.
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Figure 3 Turkey tissue distribution of 24B-1A mRNA
The tissue distribution of 24B-1A mRNA was determined by RNase protection analysis using
a 32P-labelled 24B-1A antisense cRNA probe (full length, 370 bases ; protected length, 315
bases) as described in the Materials and methods section. A 5 µg sample of total RNA was
used from each tissue, except where noted. The reaction products were resolved on a 4%
acrylamide/8 M urea gel, and an autoradiograph of the gel is shown. The lanes contain : 1, adult
erythrocyte total RNA ; 2, adult erythrocyte mRNA (0.7 µg) ; 3, brain ; 4, heart ; 5, lung ; 6, liver ;
7, kidney ; 8, intestine ; 9, skeletal muscle. The mobilities of the full-length probe (F) and the
protected probe (P) are indicated.
Figure 4 Comparison of purified native PLC-β t, rPLC-β t, rPLC-β2 and
rPLC-β1 by immunoblot analysis and silver staining
A sample of 60 ng of each purified PLC-β isoenzyme was subjected to SDS/PAGE and stained
with silver nitrate (A) or transferred to nitrocellulose (B–D) and immunoblotted with polyclonal
antisera 246 raised against purified native PLC-β t (B), PLC-β2-specific peptide antisera (C)
or PLC-β1-specific peptide antisera (D). The mobilities of molecular mass markers (kDa) are
indicated on each side.
substrate. Both enzymes also exhibited a similar dependence on
free Ca#+. Half-maximal activity was observed at 0.2 µM Ca#+,
and maximal activity was observed at approx. 1–3 µM Ca#+
(Figure 5, lower panel).
Activation of PLC-βt and rPLC-βt by Gα
""
occurred over the
same range of Gα
""
concentrations, and similar levels of maximal
activation were observed (Figure 6, left panel). G-protein βγ-
subunit also activated rPLC-βt to the same extent and over the
same range of βγ-subunit concentrations as observed for native
PLC-βt (Figure 6, right panel). As previously demonstrated for
the native enzyme, approx. 30-fold higher concentrations of βγ-
subunit than of Gα
""
were required for activation.
Activation of native and rPLC-βt by either Gα
""
or βγ-subunit
was also compared with activation of rPLC-β1 and rPLC-β2
Figure 5 Comparison of total catalytic activities of native PLC-β t and
rPLC-β t
Upper panel : the indicated concentrations of purified native (E) and recombinant (D) PLC-
β t enzymes were assayed for 5 min at 30 °C using mixed detergent and phospholipid micelles
as described in the Materials and methods section. Final reagent concentrations included :
100 µM free Ca2+, 50 µM [3H]PtdIns(4,5)P2 and 0.5% sodium cholate. Lower panel : samples
of 14 ng of purified native (E) or recombinant (D) PLC-β t were assayed for 4 min at 30 °C
in the presence of mixed detergent and phospholipid micelles containing (final concentrations)
200 µM Ptd[3H]Ins(4,5)P2, 0.5% sodium cholate and the indicated concentrations of free Ca
2+.
(Figure 7). The regulated activities of the native and recombinant
turkey enzymes were indistinguishable at three different concen-
trations of enzyme. Under these conditions the turkey enzymes
exhibited Gα
""
-stimulated activities that were approx. 5-fold
higher than that of PLC-β2 and 2-fold lower than that of PLC-
β1 (Figure 7, upper panel). Similar results were obtained in
experiments in which the concentration of PLC-βt, PLC-β1 or
PLC-β2 was held constant and the concentration of Gα
""
was
varied over a 100-fold range (results not shown). Activities of
PLC-βt observed in the presence of G-protein βγ-subunit were
approx. 2-fold greater than for rPLC-β2 (Figure 7, lower panel).
Similar results were obtained in experiments in which the
concentration of PLC-βt or PLC-β2 was held constant and the
concentration of βγ-subunit was varied over a 100-fold range
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Figure 6 Gα11 and G-protein βγ-subunit regulation of purified native PLC-β t and rPLC-β t
Left panel : concentration-dependence of purified native turkey erythrocyte Gα11 for activation of native and recombinant PLC-β t. The indicated final concentrations of Gα11 were reconstituted with
10 ng of PLC-β t (E) or rPLC-β t (D) using the dialysis protocol described in the Materials and methods section. Assays were for 7 min at 30 °C in the presence or absence of 20 µM AlCl3
and 10 mM NaF (AlF4−). The data are the means of two experiments, expressed as a percentage of the maximum AlF4−-stimulated PLC-β t activity (31 pmol/min). Right panel : concentration-
dependence of purified native bovine brain G-protein βγ-subunit for activation of native and recombinant PLC-β t. The indicated final concentrations of βγ-subunit were reconstituted with 10 ng
of PLC-β t (E) or rPLC-β t (D) using the dialysis protocol described in the Materials and methods section. Assays were for 7 min at 30 °C. The data are the means of two experiments, expressed
as a percentage of the maximum βγ-stimulated PLC-β t activity.
(results not shown). As we and others have previously demon-
strated [8,9,11,25,26], βγ-subunit had little effect on the activity
of rPLC-β1 under any of these conditions.
DISCUSSION
We have isolated a cDNA from a turkey erythrocyte cDNA
library that encodes a 139 kDa protein exhibiting sequence
similarity with PLC isoenzymes of the β-isotype. Comparison of
the predicted amino acid sequence of this cDNA with amino acid
sequence generated from the purified native protein confirmed
that the cloned cDNA encodes the PLC-β isoenzyme studied
extensively in the turkey erythrocyte model. PLC-βt was ex-
pressed in Sf9 cells after construction of a baculovirus expression
vector, the recombinant protein was purified to homogeneity,
and the physical, catalytic and regulatory properties of this
protein were directly compared with those of native PLC-βt
purified from turkey erythrocytes. The elution properties of the
recombinant and native isoenzymes were identical during chrom-
atography with five different matrices, and recombinant and
native PLC-βt shared immunoreactivity against rabbit polyclonal
antisera raised against purified PLC-βt. Moreover, the catalytic
activity of the recombinant and native enzymes with
PtdIns(4,5)P
#
as substrate in the presence of cholate, their
activation by Ca#+ and their regulated activities upon recon-
stitution with Gα
""
and βγ-subunits were indistinguishable. Thus
a cDNA encoding the turkey erythrocyte PLC-β has been cloned,
and as we have previously found to be the case with mammalian
PLC-β1 and PLC-β2 [24], the baculovirus}Sf9 cell expression
system can be utilized to produce large amounts of homogeneous
rPLC-βt that is apparently identical to the native protein.
The turkey erythrocyte enzyme is less than 50% similar at the
amino acid level to mammalian PLC-β1, PLC-β3 and PLC-β4,
to Drosophila Norp A and PLC-21, and to Xenopus PLC-βX,
indicating that PLC-βt does not represent a species homologue
of these previously cloned PLC-β isoenzymes. In contrast, the
69–71% identity of PLC-βt with mammalian PLC-β2 places the
turkey erythrocyte enzyme at least within the lower range of
identities encountered with species homologues. We have isolated
cDNAs encoding the other two protein cohorts of the turkey
erythrocyte inositol lipid signalling cascade, and these cDNAs
predict proteins that are approx. 98% (Gα
""
[18]) and 88% (P
#Y
-
purinergic receptor [19]) identical to their mammalian counter-
parts. We also have isolated a partial cDNA for turkey PLC-β1
(G. L. Waldo, unpublished work) that predicts an amino acid
sequence that is 96% and 94% identical to those of rat PLC-β1
and bovine PLC-β1 respectively. PLC-βt and mammalian PLC-
β2 are only 75% identical over the analogous amino acid
sequence, and the identity of PLC-βt with other PLC-β iso-
enzymes is less than 60% in this region. Relatively little is known
about the potential existence of splice variants of PLC-β iso-
enzymes. However, nothing in our work discounts the possibility
that turkey erythrocytes express a splice variant of PLC-β2 that
has not been previously recognized in other species. Isolation of
cDNA that clearly encoded turkey PLC-β2 or that clearly
encoded a mammalian homologue of the turkey erythrocyte
enzyme will be necessary to resolve the question of equivalence
of the cloned turkey erythrocyte enzyme with mammalian PLC-
β2. Perhaps the conundrum of their equivalence is a moot
question, in that PLC-βt and mammalian PLC-β2 exhibit dif-
ferent properties. PLC-β2 does not co-migrate with the turkey
enzyme during SDS}PAGE, and PLC-β2 and PLC-βt exhibit
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Figure 7 Comparison of Gα11 and G-protein βγ-subunit regulation of native
PLC-β t, rPLC-β t, rPLC-β1 and rPLC-β2
The indicated concentrations of purified PLC-β t (E), rPLC-β t (D), rPLC-β1 (*) or rPLC-
β2 (^) were reconstituted in unilamellar vesicles with 0.3 nM Gα11 (upper panel) or 10 nM
βγ-subunit (lower panel) using the dialysis protocol described in the Materials and methods
section. Assays of Gα11-promoted activation were in the presence or absence of AlF4−, and
AlF4−-stimulated activity is shown (upper panel). All assays were for 5 min at 30 °C.
different immunoreactivities. Moreover, PLC-βt is activated by
lower concentrations of Gα
""
compared with those necessary for
activation of PLC-β2, and PLC-βt is more sensitive than either
mammalian PLC-β1 or PLC-β2 to activation by βγ-subunit.
Overall percentage identities among the PLC-β isoenzymes
may be less important than identities in specific regions, since the
highly conserved X- and Y-domains comprise such a large
proportion of PLC isoenzymes. Since the domains responsible
for G-protein α- and βγ-subunit activation have not been
unambiguously defined, we can only speculate on the significance
of marked divergences in sequence from other PLC-β isoenzymes
found in regions outside the X- and Y-domains of PLC-βt.
Several lines of evidence suggest that activation of PLC-β
isoenzymes by α-subunits of the Gq family of G-proteins occurs
primarily through interactions in the C-terminal domain of these
enzymes [27–29]. Thus it may prove useful to establish whether
the C-terminal extension found in the turkey enzyme plays a role
in differences in the α-subunit regulation of PLC-βt compared
with PLC-β2, and the functional significance, if any, of divergence
in the sequences of PLC-βt and PLC-β2 elsewhere in the
C-terminal domain should be established. Little is known about
the domain(s) of PLC-β isoenzymes involved in βγ-subunit
regulation, although regions outside the C-terminal domain
are apparently responsible [29–31]. PLC-βt is one of the most
sensitive to βγ-subunit activation of any of the known PLC-β
isoenzymes, and availability of cDNA encoding the turkey
isoenzyme should now allow us to delineate the domain involved
in βγ-subunit regulation in an isoenzyme that is markedly
activated by both α- and βγ-subunits. The relative importance of
the poorly conserved sequence (residues 468–576) in the domain
between the X- and Y-domains is not known, but this sequence
in PLC-βt, which differs markedly from sequences in other
PLC-β isoenzymes, could eventually provide an insight into the
functionality of this domain.
James et al. [32,33] and Boguslavsky et al. [34] have reported
that native PLC-βt binds with high affinity to polyphospho-
inositide-containing phospholipid vesicles. In contrast, rPLC-β2
and rPLC-β1 exhibit markedly lower binding affinities (S. R.
James, A. Paterson, T. K. Harden and C. P. Downes, unpub-
lished work). The availability of cDNA encoding PLC-βt should
allow us to begin to address the structural basis of differences
observed among these proteins in their capacity to interact with
phospholipid membranes and PtdIns(4,5)P
#
.
A so-called pleckstrin homology domain has been identified in
nearly 100 different proteins [35]. Although the function(s) of this
domain has not been unambiguously established, a role in
membrane targeting has been strongly implicated. Thus it is not
surprising that PLC isoenzymes, including those of the PLC-β
class, possess pleckstrin homology domains [36]. The predicted
sequence of PLC-βt also includes a pleckstrin homology domain
in the N-terminus and thus provides an additional protein
sequence in which the function of such a domain and the
potential importance of its interaction with G-protein βγ-
subunits can be established.
We know from studies with intact erythrocytes that the P
#Y
-
purinergic-receptor-regulated inositol lipid signalling cascade is
very sensitive to inhibition by elevation of intracellular cAMP
(M. C. Galas and T. K. Harden, unpublished work) and pre-
sumably by activation of cAMP-dependent protein kinase. In
contrast to PLC-β2, we have found that PLC-βt is also an
excellent in itro substrate for cAMP-dependent protein kinase
(A. Paterson, G. L. Waldo and T. K. Harden, unpublished
work). Several consensus sites for phosphorylation by cAMP-
dependent protein kinase are uniquely found in PLC-βt, and we
are currently establishing the role of these sites in regulation of
enzyme activity.
We have previously purified large amounts (up to 30 mg) of
homogeneous rPLC-β1 and rPLC-β2 after baculovirus ex-
pression in Sf9 cells [24]. Although we have not yet generated
large-scale preparations of homogeneous PLC-βt, the baculo-
virus expression system apparently works equally well for pro-
duction of homogeneous turkey enzyme. The fidelity with which
rPLC-βt retains the physical and regulatory properties of native
PLC-βt supports the idea that baculovirus-promoted expression
of PLC isoenzymes in Sf9 insect cells provides an ideal approach
for preparation of large amounts of these effector proteins in a
homogeneous form. This should prove highly advantageous for
the unambiguous definition of α- and βγ-subunit regulatory
domains in PLC-βt, for delineation of amino acid residues
important in phospholipid surface binding, and for delineation
of important phosphorylation sites in this effector protein.
In summary, a cDNA encoding PLC-βt has been cloned and
the recombinant protein has been expressed, purified and charac-
terized. We have now isolated the cDNAs for all three protein
cohorts of a receptor-regulated PLC of a homogeneous cell,
which places us in a position to reconstruct a receptor–G-
protein–effector-protein cascade from a single cell type.
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